Balance Sheet
Accumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CASI Pharmaceuticals (CASI) Total Current Liabilities (2021 - 2025)

Historic Total Current Liabilities for Pharmaceuticals (CASI) over the last 5 years, with Q2 2025 value amounting to $37.7 million.

  • Pharmaceuticals' Total Current Liabilities fell 9960.62% to $37.7 million in Q2 2025 from the same period last year, while for Jun 2025 it was $37.7 million, marking a year-over-year decrease of 9960.62%. This contributed to the annual value of $36.5 million for FY2024, which is 9978.21% down from last year.
  • Latest data reveals that Pharmaceuticals reported Total Current Liabilities of $37.7 million as of Q2 2025, which was down 9960.62% from $33.7 billion recorded in Q1 2025.
  • Over the past 5 years, Pharmaceuticals' Total Current Liabilities peaked at $33.7 billion during Q1 2025, and registered a low of $8.5 million during Q1 2024.
  • Over the past 5 years, Pharmaceuticals' median Total Current Liabilities value was $37.7 million (recorded in 2025), while the average stood at $8.0 billion.
  • In the last 5 years, Pharmaceuticals' Total Current Liabilities plummeted by 9978.21% in 2024 and then skyrocketed by 39448099.25% in 2025.
  • Pharmaceuticals' Total Current Liabilities (Quarter) stood at $13.2 million in 2021, then increased by 28.96% to $17.0 million in 2022, then skyrocketed by 98259.31% to $16.7 billion in 2023, then plummeted by 99.78% to $36.5 million in 2024, then rose by 3.53% to $37.7 million in 2025.
  • Its Total Current Liabilities stands at $37.7 million for Q2 2025, versus $33.7 billion for Q1 2025 and $36.5 million for Q4 2024.